While BRAFV600E mutations have a very high frequency in both PTC and ATC tumours (59.7% and 45%, respectively), mutational changes in PIK3CA are only present in 0.5% of PTC patient samples and at a much higher frequency of 18% in ATC [8, 9]. This evidence concerns the gene PIK3CA and neoplasm.